Περίληψη:
PURPOSE: To assess the efficacy of the anti-TNF monoclonal antibody
infliximab in uveitis patients without clinically evident ocular
inflammation and impaired visual acuity because of chronic cystoid
macular edema (CME).
DESIGN: Prospective, noncomparative, interventional case series.
METHODS: Patients with refractory CME (14 eyes, mean duration of 14
months), associated with intermediate uveitis (n = 6),
Adamantiades-Behcet disease (n = 2), adult-type vascular pseudotumor (n
= 1), and HLAB27+-related uveitis (n = 1) received an intravenous
infliximab infusion (5 mg/kg); five patients were retreated after 1
month.
RESULTS: Macular thickness, measured by ocular coherence tomography, was
reduced from 428 +/- 138 mum to 219 +/- 51 mum at 2 months postbaseline
(P = .0001), while visual acuity increased from 0.41 +/- 0.18 to 0.83
+/- 0.17 (P < .00001). Anatomic and functional improvement was sustained
at 6 months in all. No ocular or extra-ocular side effects were noted.
CONCLUSION: These promising results suggest that TNF may play an
important pathogenetic role in chronic CME, thus, a controlled trial is
warranted. (C) 2004 by Elsevier Inc. All rights reserved.
Συγγραφείς:
Markomichelakis, NN
Theodossiadis, PG
Pantelia, E and
Papaefthimiou, S
Theodossiadis, GP
Sfikakis, PP
